{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:46:35Z","timestamp":1787791595537,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012415","name":"Biomedical Research Council","doi-asserted-by":"publisher","award":["BMRC\/05\/1\/21\/19\/425"],"award-info":[{"award-number":["BMRC\/05\/1\/21\/19\/425"]}],"id":[{"id":"10.13039\/501100012415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/0850\/2004"],"award-info":[{"award-number":["NMRC\/0850\/2004"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["OFLCG\/001\/2017"],"award-info":[{"award-number":["OFLCG\/001\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00125-025-06498-0","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:28:11Z","timestamp":1753918091000},"page":"2227-2239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health economic evaluation of a risk-stratified intervention in diabetic kidney disease"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9429-2627","authenticated-orcid":false,"given":"Tosha A.","family":"Kalhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Hui","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Shyong","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Chi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-6998","authenticated-orcid":false,"given":"Kavita","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"6498_CR1","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K et al (2015) Diabetic kidney disease. Nat Rev Dis Primers 1:15018. https:\/\/doi.org\/10.1038\/nrdp.2015.18","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"6498_CR2","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.mayocp.2022.05.003","volume":"97","author":"R Alicic","year":"2022","unstructured":"Alicic R, Nicholas SB (2022) Diabetic kidney disease back in focus: management field guide for health care professionals in the 21st century. Mayo Clin Proc 97(10):1904\u20131919. https:\/\/doi.org\/10.1016\/j.mayocp.2022.05.003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"6498_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24(2):302. https:\/\/doi.org\/10.1681\/ASN.2012070718","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"6498_CR4","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.18553\/jmcp.2020.26.12.1506","volume":"26","author":"K Folkerts","year":"2020","unstructured":"Folkerts K, Petruski-Ivleva N, Kelly A et al (2020) Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database. J Manag Care Spec Pharm 26(12):1506\u20131516. https:\/\/doi.org\/10.18553\/jmcp.2020.26.12.1506","journal-title":"J Manag Care Spec Pharm"},{"issue":"Suppl 1","key":"6498_CR5","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2337\/dc23-S011","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2022) 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142023. Diabetes Care 46(Suppl 1):S191\u2013S202. https:\/\/doi.org\/10.2337\/dc23-S011","journal-title":"Diabetes Care"},{"issue":"7","key":"6498_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2215\/cjn.02980322","volume":"17","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Wong L, St Peter W et al (2022) Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 17(7):1092\u20131103. https:\/\/doi.org\/10.2215\/cjn.02980322","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"6498_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s40273-019-00835-z","volume":"37","author":"DM Sugrue","year":"2019","unstructured":"Sugrue DM, Ward T, Rai S, McEwan P, van Haalen HGM (2019) Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design. PharmacoEconomics 37(12):1451\u20131468. https:\/\/doi.org\/10.1007\/s40273-019-00835-z","journal-title":"PharmacoEconomics"},{"issue":"7246","key":"6498_CR8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/bmj.320.7246.1373","volume":"320","author":"A Gray","year":"2000","unstructured":"Gray A, Raikou M, McGuire A et al (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320(7246):1373. https:\/\/doi.org\/10.1136\/bmj.320.7246.1373","journal-title":"BMJ"},{"issue":"6","key":"6498_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/ndt\/gfh802","volume":"20","author":"AJ Palmer","year":"2005","unstructured":"Palmer AJ, Tucker DMD, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ (2005) Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 20(6):1103\u20131109. https:\/\/doi.org\/10.1093\/ndt\/gfh802","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"6498_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13300-020-00968-x","volume":"12","author":"M Willis","year":"2021","unstructured":"Willis M, Nilsson A, Kellerborg K et al (2021) Cost-effectiveness of canagliflozin added to standard of care for treating diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM) in England: estimates using the CREDEM-DKD model. Diabetes Ther 12(1):313\u2013328. https:\/\/doi.org\/10.1007\/s13300-020-00968-x","journal-title":"Diabetes Ther"},{"issue":"6","key":"6498_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2021.09.014","volume":"79","author":"OS Reifsnider","year":"2022","unstructured":"Reifsnider OS, Kansal AR, Wanner C et al (2022) Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial. Am J Kidney Dis 79(6):796\u2013806. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6498_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","volume":"39","author":"JJ Garcia Sanchez","year":"2022","unstructured":"Garcia Sanchez JJ, Thompson J, Scott DA et al (2022) Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv Ther 39(1):193\u2013220. https:\/\/doi.org\/10.1007\/s12325-021-02006-z","journal-title":"Adv Ther"},{"key":"6498_CR13","unstructured":"United States Renal Data System (2021) 2021 USRDS annual data report: end stage renal disease. National Institute of Health, Unites States"},{"issue":"2","key":"6498_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.ajkd.2020.11.026","volume":"78","author":"O Swartling","year":"2021","unstructured":"Swartling O, Rydell H, Stendahl M, Segelmark M, TrolleLagerros Y, Evans M (2021) CKD progression and mortality among men and women: a nationwide study in Sweden. Am J Kidney Dis 78(2):190-199.e191. https:\/\/doi.org\/10.1053\/j.ajkd.2020.11.026","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"6498_CR15","doi-asserted-by":"publisher","first-page":"e3013","DOI":"10.1097\/MD.0000000000003013","volume":"95","author":"W-C Tsai","year":"2016","unstructured":"Tsai W-C, Wu H-Y, Peng Y-S et al (2016) Risk factors for development and progression of chronic kidney disease: a systematic review and exploratory meta-analysis. Medicine (Baltimore) 95(11):e3013\u2013e3013. https:\/\/doi.org\/10.1097\/MD.0000000000003013","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"6498_CR16","doi-asserted-by":"publisher","first-page":"e020145","DOI":"10.1136\/bmjopen-2017-020145","volume":"8","author":"R Mathur","year":"2018","unstructured":"Mathur R, Dreyer G, Yaqoob MM, Hull SA (2018) Ethnic differences in the progression of chronic kidney disease and risk of death in a UK diabetic population: an observational cohort study. BMJ Open 8(3):e020145. https:\/\/doi.org\/10.1136\/bmjopen-2017-020145","journal-title":"BMJ Open"},{"issue":"5","key":"6498_CR17","doi-asserted-by":"publisher","first-page":"e036443","DOI":"10.1136\/bmjopen-2019-036443","volume":"10","author":"M Luo","year":"2020","unstructured":"Luo M, Tan LWL, Sim X et al (2020) Cohort profile: the Singapore diabetic cohort study. BMJ Open 10(5):e036443. https:\/\/doi.org\/10.1136\/bmjopen-2019-036443","journal-title":"BMJ Open"},{"issue":"5s","key":"6498_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102(5s):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"6498_CR19","unstructured":"National Registry of Diseases Office (NRDO) (2018) Singapore Renal Registry annual report 2016. Available from https:\/\/www.nrdo.gov.sg\/docs\/librariesprovider3\/default-document-library\/singapore-renal-registry-annual-report-2016_1999-till-2016_v5_online_final.pdf?sfvrsn=0. Accessed 4 Aug 2024"},{"issue":"11","key":"6498_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825\u2013830. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007","journal-title":"Ann Intern Med"},{"issue":"10","key":"6498_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke PM, Gray AM, Briggs A et al (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47(10):1747\u20131759. https:\/\/doi.org\/10.1007\/s00125-004-1527-z","journal-title":"Diabetologia"},{"issue":"7","key":"6498_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jdiacomp.2016.05.020","volume":"30","author":"S Low","year":"2016","unstructured":"Low S, Tai ES, Yeoh LY et al (2016) Onset and progression of kidney disease in type 2 diabetes among multi-ethnic Asian population. J Diabetes Complications 30(7):1248\u20131254. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.05.020","journal-title":"J Diabetes Complications"},{"issue":"7","key":"6498_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"10166","key":"6498_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(18)32590-x","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(18)32590-x","journal-title":"Lancet"},{"issue":"12","key":"6498_CR25","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2215\/cjn.10140620","volume":"15","author":"G Bakris","year":"2020","unstructured":"Bakris G, Oshima M, Mahaffey KW et al (2020) Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m(2): Subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol 15(12):1705\u20131714. https:\/\/doi.org\/10.2215\/cjn.10140620","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"6498_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"24","key":"6498_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"6","key":"6498_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1365-2265.2012.04480.x","volume":"78","author":"K Venkataraman","year":"2013","unstructured":"Venkataraman K, Wee HL, Leow MK et al (2013) Associations between complications and health-related quality of life in individuals with diabetes. Clin Endocrinol (Oxf) 78(6):865\u2013873. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04480.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"6498_CR29","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s11136-015-0964-0","volume":"24","author":"F Yang","year":"2015","unstructured":"Yang F, Griva K, Lau T et al (2015) Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore. Qual Life Res 24(9):2163\u20132171. https:\/\/doi.org\/10.1007\/s11136-015-0964-0","journal-title":"Qual Life Res"},{"key":"6498_CR30","unstructured":"OECD (2024) Data Purchasing power parities (PPP). Available from https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm. Accessed 4 Aug 2024"},{"issue":"5","key":"6498_CR31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.numecd.2021.02.006","volume":"31","author":"Y Bai","year":"2021","unstructured":"Bai Y, Jin J, Zhou W, Zhang S, Xu J (2021) The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 31(5):1365\u20131374. https:\/\/doi.org\/10.1016\/j.numecd.2021.02.006","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"6498_CR32","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ"},{"issue":"6","key":"6498_CR33","doi-asserted-by":"publisher","first-page":"e0126427","DOI":"10.1371\/journal.pone.0126427","volume":"10","author":"CL Edridge","year":"2015","unstructured":"Edridge CL, Dunkley AJ, Bodicoat DH et al (2015) Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One 10(6):e0126427. https:\/\/doi.org\/10.1371\/journal.pone.0126427","journal-title":"PLoS One"},{"key":"6498_CR34","doi-asserted-by":"publisher","first-page":"728911","DOI":"10.3389\/fphar.2021.728911","volume":"12","author":"M Ambro\u017e","year":"2021","unstructured":"Ambro\u017e M, de Vries ST, Hoogenberg K, Denig P (2021) Older age, polypharmacy, and low systolic blood pressure are associated with more hypotension-related adverse events in patients with type 2 diabetes treated with antihypertensives. Front Pharmacol 12:728911. https:\/\/doi.org\/10.3389\/fphar.2021.728911","journal-title":"Front Pharmacol"},{"issue":"2","key":"6498_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S (2015) Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 93(2):118\u2013124. https:\/\/doi.org\/10.2471\/BLT.14.138206","journal-title":"Bull World Health Organ"},{"key":"6498_CR36","unstructured":"Agency for Care Effectiveness (ACE). Methods and process. Available from https:\/\/www.ace-hta.gov.sg\/resources\/process-methods. Accessed 6 March 2023"},{"issue":"7","key":"6498_CR37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","volume":"15","author":"AYL Liu","year":"2022","unstructured":"Liu AYL, Low S, Yeoh E et al (2022) A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin Kidney J 15(7):1403\u20131414. https:\/\/doi.org\/10.1093\/ckj\/sfac044","journal-title":"Clin Kidney J"},{"key":"6498_CR38","doi-asserted-by":"publisher","first-page":"765999","DOI":"10.3389\/fpubh.2021.765999","volume":"9","author":"Z Luo","year":"2021","unstructured":"Luo Z, Ruan Z, Yao D, Ung COL, Lai Y, Hu H (2021) Budget impact analysis of diabetes drugs: a systematic literature review. Front Public Health 9:765999. https:\/\/doi.org\/10.3389\/fpubh.2021.765999","journal-title":"Front Public Health"},{"key":"6498_CR39","volume-title":"Industrial and business forecasting methods: a practical guide to exponential smoothing and curve fitting","author":"CD Lewis","year":"1982","unstructured":"Lewis CD (1982) Industrial and business forecasting methods: a practical guide to exponential smoothing and curve fitting. Butterworth-Heinemann, Oxford"},{"key":"6498_CR40","doi-asserted-by":"publisher","unstructured":"Chen Y, Bakker SJL, Suthahar N et al (2023) Transitions across kidney disease stages and association with new-onset heart failure: a population-based study of 8569 individuals and 12.6 years of follow-up. medRxiv: 2022.2012.2031.22284047. https:\/\/doi.org\/10.1101\/2022.12.31.22284047","DOI":"10.1101\/2022.12.31.22284047"},{"key":"6498_CR41","doi-asserted-by":"publisher","first-page":"100946","DOI":"10.1016\/j.cegh.2021.100946","volume":"13","author":"MK Lintu","year":"2022","unstructured":"Lintu MK, Shreyas KM, Kamath A (2022) A multi-state model for kidney disease progression. Clin Epidemiol Global Health 13:100946. https:\/\/doi.org\/10.1016\/j.cegh.2021.100946","journal-title":"Clin Epidemiol Global Health"},{"issue":"6","key":"6498_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40261-022-01160-8","volume":"42","author":"TM Abegaz","year":"2022","unstructured":"Abegaz TM, Diaby V, Sherbeny F, Ali AA (2022) Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA. Clin Drug Investig 42(6):501\u2013511. https:\/\/doi.org\/10.1007\/s40261-022-01160-8","journal-title":"Clin Drug Investig"},{"issue":"10","key":"6498_CR43","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1111\/dom.15201","volume":"25","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Mital S, Bugden S, Nguyen HV (2023) Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab 25(10):3030\u20133039. https:\/\/doi.org\/10.1111\/dom.15201","journal-title":"Diabetes Obes Metab"},{"key":"6498_CR44","unstructured":"Ministry of Health Singapore (2019) speech by Mr Chan Heng Kee, Permanent Secretary, Ministry Of Health, at the 3rd Kidney Care Conference 2019, 25 May 2019. Available from https:\/\/www.moh.gov.sg\/news-highlights\/details\/speech-by-mr-chan-heng-kee-permanent-secretary-ministry-of-health-at-the-3rd-kidney-care-conference-2019-25-may-2019. Accessed 13 March 2023"},{"key":"6498_CR45","unstructured":"Ministry of Health Singapore (2022) White Paper on Healthier SG. Available from https:\/\/www.moh.gov.sg\/news-highlights\/details\/white-paper-on-healthier-sg. Accessed 4 Aug 2024"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06498-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:02:06Z","timestamp":1785369726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06498-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6498"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06498-0","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data used in this study are from the MOH administrative datasets and are not publicly available. Requests for onsite access to the anonymised data for research may be made to the MOH.","order":1,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was funded by grants from the National Medical Research Council, Singapore (OFLCG\/001\/2017, NMRC\/0850\/2004); the Biomedical Research Council of A-Star (BMRC\/05\/1\/21\/19\/425); the Ministry of Health, Singapore; the National University of Singapore; and the National University Health System.","order":2,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"TAK and ML planned the methodology, performed data curation and analysis, wrote the first draft of the manuscript and critically reviewed the manuscript for important intellectual content. JHC planned the methodology, performed data analysis and critically reviewed the manuscript for important intellectual content. EST was involved in conceptualisation, funding acquisition and data interpretation and critically reviewed the manuscript for important intellectual content. SCL and TMC were involved in funding acquisition and data interpretation and critically reviewed the manuscript for important intellectual content. KV was involved in conceptualisation, funding acquisition, planning the methodology, data curation and data interpretation and critically reviewed the manuscript for important intellectual content. All authors were entitled to full access to all the data in the study, read and approved the final manuscript, and had final responsibility for the decision to submit for publication. KV is the guarantor of this work and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}